180 Life Sciences is a biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing research, and, where appropriate, combination therapy. Co.'s product development platforms that are focused on different diseases or medical conditions, and that target different factors, molecules or proteins, include: anti-tumor necrosis factor (TNF) platform, which is focusing on fibrosis and anti-TNF; synthetic cannabidiol analogs platform, which is focusing on drugs which are synthetic cannabidiol or cannabigerol analogues; and alpha 7 nicotinic acetylcholine receptor (a7nAChR) platform, which is focusing on a7nAChR. The ATNF average annual return since 2017 is shown above.
The Average Annual Return on the ATNF average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ATNF average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ATNF average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|